The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Optimal Structure Requirements for Pluronic Block Copolymers in Modifying P-glycoprotein Drug Efflux Transporter Activity in Bovine Brain Microvessel Endothelial Cells
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
BIOCHEMICAL, CELLULAR, AND PHARMACOLOGICAL ASPECTS OF THE MULTIDRUG TRANSPORTER
Ambudkar, S. V., Dey, S., Hrycyna, C. A., Ramachandra, M., Pastan, I., & Gottesman, M. M. (1999) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.39.1.361 · Cited by 2,059
Alexandridis, P., Holzwarth, J. F., & Hatton, T. A. (1994) · Macromolecules · doi:10.1021/ma00087a009 · Cited by 1,862
Microviscosity parameters and protein mobility in biological membranes
Shinitzky, M., & Inbar, M. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90183-8 · Cited by 675
MTT colorimetric assay for testing macrophage cytotoxic activity in vitro
Ferrari, M., Fornasiero, M. C., & Isetta, A. M. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90187-z · Cited by 565
Prendergast, F. G., Haugland, R. P., & Callahan, P. J. (1981) · Biochemistry · doi:10.1021/bi00529a002 · Cited by 492
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Kabanov, A. V., Chekhonin, V. P., Alakhov, V. Y., Batrakova, E. V., Lebedev, A. S., Melik-Nubarov, N. S., Arzhakov, S. A., Levashov, A. V., Morozov, G. V., Severin, E. S., et al. (1989) · FEBS Letters · doi:10.1016/0014-5793(89)81689-8 · Cited by 296
Self-citationBatrakova, E. V., Li, S., Vinogradov, S. V., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29254-5 · Cited by 292
Self-citationVenne, A., Li, S., Mandeville, R., Kabanov, A. V., & Alakhov, V. Y. (1996) · PubMed · Cited by 225
Self-citationA combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle
Lemieux, P., Guérin, N., Paradis, G., Proulx, R., Chistyakova, L., Kabanov, A., & Alakhov, V (2000) · Gene Therapy · doi:10.1038/sj.gt.3301189 · Cited by 213
Self-citation
Cited by
Nanomedicine: current status and future prospects
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2005) · The FASEB Journal · doi:10.1096/fj.04-2747rev · Cited by 2,029
“Certain polymeric constituents used in nanoparticle design and engineering act as inhibitors of P-glycoprotein efflux pumps expressed in polarized endothelial cells that form the exterior of the blood-brain barrier (145), and could potentially interfere with transport of a number of modulators and homeostatic mediator…”
BackgroundDevelopment of exosome-encapsulated paclitaxel to overcome MDR in cancer cells
Kim, M. S., Haney, M. J., Zhao, Y., Mahajan, V., Deygen, I., Klyachko, N. L., Inskoe, E., Piroyan, A., Sokolsky, M., Okolie, O., et al. (2016) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2015.10.012 · Cited by 1,410
Self-citationBatrakova, E. V., & Kabanov, A. V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2008.04.013 · Cited by 1,278
“It was demonstrated that a fine balance between hydrophilic (EO) and lipophilic (PO) components in the Pluronic molecule should be accomplished to potent enable inhibition of the drug efflux systems in MDR cells [63].”
BackgroundInfluentialSelf-citationModern methods for delivery of drugs across the blood–brain barrier
Chen, Y., & Liu, L. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.11.010 · Cited by 1,006
Role of nanotechnology in targeted drug delivery and imaging: a concise review
Koo, O. M., Rubinstein, I., & Onyuksel, H. (2005) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2005.06.004 · Cited by 718
Overcoming the Blood–Brain Barrier: The Role of Nanomaterials in Treating Neurological Diseases
Furtado, D., Björnmalm, M., Ayton, S., Bush, A. I., Kempe, K., & Caruso, F. (2018) · Advanced Materials · doi:10.1002/adma.201801362 · Cited by 708
Kim, S., Shi, Y., Kim, J. Y., Park, K., & Cheng, J.-X. (2010) · Expert Opinion on Drug Delivery · doi:10.1517/17425240903380446 · Cited by 549
Nanotechnological advances for the delivery of cns therapeutics.
Wong, H. L., Wu, X. Y., & Bendayan, R. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2011.10.007 · Cited by 488
Pitto-Barry, A., & Barry, N. P. E. (2014) · Polym. Chem. · doi:10.1039/c4py00039k · Cited by 464
Polymeric micelles for drug delivery
Aliabadi, H. M., & Lavasanifar, A. (2006) · Expert Opinion on Drug Delivery · doi:10.1517/17425247.3.1.139 · Cited by 446
Wei, Z., Hao, J., Yuan, S., Li, Y., Juan, W., Sha, X., & Fang, X. (2009) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2009.04.030 · Cited by 427
Recent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives
Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394
Binkhathlan, Z., & Lavasanifar, A. (2013) · Current Cancer Drug Targets · doi:10.2174/15680096113139990076 · Cited by 390
Nanostructured Pluronic hydrogels as bioinks for 3D bioprinting
Müller, M., Becher, J., Schnabelrauch, M., & Zenobi-Wong, M. (2015) · Biofabrication · doi:10.1088/1758-5090/7/3/035006 · Cited by 371
Zhang, W., Shi, Y., Chen, Y., Ye, J., Sha, X., & Fang, X. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.039 · Cited by 368
Nanomedicinal Strategies to Treat Multidrug-Resistant Tumors: Current Progress
Dong, X., & Mumper, R. J. (2010) · Nanomedicine · doi:10.2217/nnm.10.35 · Cited by 317
Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo
Cornaire, G., Woodley, J., Hermann, P., Cloarec, A., Arellano, C., & Houin, G. (2004) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2004.03.001 · Cited by 307
Nanotechnologies for Alzheimer's disease: diagnosis, therapy, and safety issues
Brambilla, D., Le Droumaguet, B., Nicolas, J., Hashemi, S. H., Wu, L.-P., Moghimi, S. M., Couvreur, P., & Andrieux, K. (2011) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2011.03.008 · Cited by 294
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Self-citationPluronics and MDR reversal: an update
Alakhova, D. Y., & Kabanov, A. V. (2014) · Molecular Pharmaceutics · doi:10.1021/mp500298q · Cited by 224
Self-citationNovel poloxamer-based nanoemulsions to enhance the intestinal absorption of active compounds
BRUSEWITZ, C., SCHENDLER, A., FUNKE, A., WAGNER, T., & LIPP, R. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.08.022 · Cited by 86
Sakai-Kato, K., Nishiyama, N., Kozaki, M., Nakanishi, T., Matsuda, Y., Hirano, M., Hanada, H., Hisada, S., Onodera, H., Harashima, H., et al. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.05.259 · Cited by 75
WANG, Y., LI, Y., WANG, Q., WU, J., & FANG, X. (2008) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.128.941 · Cited by 29
Metadata
- Authors
- Batrakova, E. V., Li, S., Alakhov, V. Y., Miller, D. W., & Kabanov, A. V.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2003-02
- Volume
- 304
- Issue
- 2
- Pages
- 845-854
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2092738808
- Cited by
- 263
- References
- 28
- FWCI
- 5.54
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.